126 related articles for article (PubMed ID: 25226890)
1. Controlled release bevacizumab in thermoresponsive hydrogel found to inhibit angiogenesis.
Hu CC; Chaw JR; Chen CF; Liu HW
Biomed Mater Eng; 2014; 24(6):1941-50. PubMed ID: 25226890
[TBL] [Abstract][Full Text] [Related]
2. Thermo-responsive hydrogel as an anti-VEGF drug delivery system to inhibit retinal angiogenesis in Rex rabbits.
Hu CC; Chiu YC; Chaw JR; Chen CF; Liu HW
Technol Health Care; 2019; 27(S1):153-163. PubMed ID: 31045535
[TBL] [Abstract][Full Text] [Related]
3. Extended release of bevacizumab by thermosensitive biodegradable and biocompatible hydrogel.
Wang CH; Hwang YS; Chiang PR; Shen CR; Hong WH; Hsiue GH
Biomacromolecules; 2012 Jan; 13(1):40-8. PubMed ID: 22145634
[TBL] [Abstract][Full Text] [Related]
4. Prevention of corneal neovascularization by subconjunctival injection of avastin® loaded thermosensitive hydrogels in rabbit model.
Xu X; Yu J; Shi H; Zhang J; Li X
Int J Pharm; 2018 Dec; 552(1-2):164-170. PubMed ID: 30217769
[TBL] [Abstract][Full Text] [Related]
5. An injectable thermosensitive polymeric hydrogel for sustained release of Avastin® to treat posterior segment disease.
Xie B; Jin L; Luo Z; Yu J; Shi S; Zhang Z; Shen M; Chen H; Li X; Song Z
Int J Pharm; 2015 Jul; 490(1-2):375-83. PubMed ID: 26027491
[TBL] [Abstract][Full Text] [Related]
6. Biocompatible reverse thermal gel sustains the release of intravitreal bevacizumab in vivo.
Rauck BM; Friberg TR; Medina Mendez CA; Park D; Shah V; Bilonick RA; Wang Y
Invest Ophthalmol Vis Sci; 2014 Jan; 55(1):469-76. PubMed ID: 24370837
[TBL] [Abstract][Full Text] [Related]
7. Controlled and Extended In Vitro Release of Bioactive Anti-Vascular Endothelial Growth Factors from a Microsphere-Hydrogel Drug Delivery System.
Osswald CR; Kang-Mieler JJ
Curr Eye Res; 2016 Sep; 41(9):1216-22. PubMed ID: 26764892
[TBL] [Abstract][Full Text] [Related]
8. Intravitreal injectable hydrogel rods with long-acting bevacizumab delivery to the retina.
Lee S; Hong HK; Song JS; Jeong SI; Chung JY; Woo SJ; Park KD
Acta Biomater; 2023 Nov; 171():273-288. PubMed ID: 37739248
[TBL] [Abstract][Full Text] [Related]
9. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration.
Rich RM; Rosenfeld PJ; Puliafito CA; Dubovy SR; Davis JL; Flynn HW; Gonzalez S; Feuer WJ; Lin RC; Lalwani GA; Nguyen JK; Kumar G
Retina; 2006; 26(5):495-511. PubMed ID: 16770255
[TBL] [Abstract][Full Text] [Related]
10. [Efficacy of three intravitreal injections of bevacizumab in the treatment of exudative age-related macular degeneration].
Bidot ML; Malvitte L; Bidot S; Bron A; Creuzot-Garcher C
J Fr Ophtalmol; 2011 Jun; 34(6):376-81. PubMed ID: 21550687
[TBL] [Abstract][Full Text] [Related]
11. Treatment of neovascular age-related macular degeneration with intravitreal bevacizumab: efficacy of three consecutive monthly injections.
Melamud A; Stinnett S; Fekrat S
Am J Ophthalmol; 2008 Jul; 146(1):91-5. PubMed ID: 18455144
[TBL] [Abstract][Full Text] [Related]
12. Retinal pigment epithelium tears after intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration.
Ronan SM; Yoganathan P; Chien FY; Corcóstegui IA; Blumenkranz MS; Deramo VA; Elner SG; Fastenberg DA; Johnson MW; López M; Mateo C; Moshfeghi DM; Navarro R; Rosenblatt BJ; Sanislo SR; Saxe SJ; Zacks DN
Retina; 2007 Jun; 27(5):535-40. PubMed ID: 17558313
[TBL] [Abstract][Full Text] [Related]
13. Biodegradable Microsphere-Hydrogel Ocular Drug Delivery System for Controlled and Extended Release of Bioactive Aflibercept In Vitro.
Liu W; Lee BS; Mieler WF; Kang-Mieler JJ
Curr Eye Res; 2019 Mar; 44(3):264-274. PubMed ID: 30295090
[TBL] [Abstract][Full Text] [Related]
14. Changes in aqueous vascular endothelial growth factor and pigment epithelial-derived factor levels following intravitreal bevacizumab injections for choroidal neovascularization secondary to age-related macular degeneration or pathologic myopia.
Chan WM; Lai TY; Chan KP; Li H; Liu DT; Lam DS; Pang CP
Retina; 2008 Oct; 28(9):1308-13. PubMed ID: 18728623
[TBL] [Abstract][Full Text] [Related]
15. Intravitreal therapy in bilateral neovascular age-related macular degeneration.
Barthelmes D; Walton RJ; Arnold JJ; McAllister IL; Simpson JM; Campain A; Hunyor AP; Guymer R; Essex RW; Morlet N; Gillies MC;
Ophthalmology; 2014 Oct; 121(10):2073-4. PubMed ID: 24939512
[No Abstract] [Full Text] [Related]
16. Synthesis, characterization, biodegradability and biocompatibility of a temperature-sensitive PBLA-PEG-PBLA hydrogel as protein delivery system with low critical gelation concentration.
Xu Y; Shen Y; Xiong Y; Li C; Sun C; Ouahab A; Tu J
Drug Dev Ind Pharm; 2014 Sep; 40(9):1264-75. PubMed ID: 23855735
[TBL] [Abstract][Full Text] [Related]
17. Primary intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration: results of the Pan-American Collaborative Retina Study Group at 12 months follow-up.
Arevalo JF; Fromow-Guerra J; Sanchez JG; Maia M; Berrocal MH; Wu L; Saravia MJ; Costa RA;
Retina; 2008; 28(10):1387-94. PubMed ID: 18827735
[TBL] [Abstract][Full Text] [Related]
18. Treatment of osteomyelitis with teicoplanin-encapsulated biodegradable thermosensitive hydrogel nanoparticles.
Peng KT; Chen CF; Chu IM; Li YM; Hsu WH; Hsu RW; Chang PJ
Biomaterials; 2010 Jul; 31(19):5227-36. PubMed ID: 20381140
[TBL] [Abstract][Full Text] [Related]
19. One-year outcomes of less frequent bevacizumab in age-related macular degeneration.
Sonmez K; Sonmez PA; Ozkan SS; Atmaca LS
Retina; 2011 Apr; 31(4):645-53. PubMed ID: 21358363
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of intravitreal bevacizumab (Avastin) therapy for early and advanced neovascular age-related macular degeneration.
Krebs I; Lie S; Stolba U; Zeiler F; Felke S; Binder S
Acta Ophthalmol; 2009 Sep; 87(6):611-7. PubMed ID: 18937801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
